natgillin/translations-raw huggingface dataset:
Neuropsykiatriske hændelser som disse er også blevet rapporteret hos patienter med influenza, som ikke fik oseltamivir.
Such neuropsychiatric events have also been reported in patients with influenza who were not taking oseltamivir.
Neuropsykiatriske hændelser som disse er også blevet rapporteret hos patienter med influenza, som ikke fik Tamiflu.
Such neuropsychiatric events have also been reported in patients with influenza who were not taking Tamiflu.
Neuropsykiatriske lidelser, som beskrevet nedenfor.
Neuropsychiatric disorders, as described below.
Neuropsykiatriske symptomer og aktivering af mani
Neuropsychiatric symptoms and activation of mania
Neurose
Neurosis
neurosensorisk døvhed
deafness neurosensory
Neuroser Dysfori
Delusional disorder, persecutory type
Neurotransmittere er kemiske signalstoffer, som nervecellerne anvender til
Neurotransmitters are chemicals that allow nerve cells to communicate with
Neurotransmittere som GABA er kemikalier, som sætter nervecellerne i stand til at kommunikere med hinanden.
Neurotransmitters such as GABA are chemicals that allow nerve cells to communicate with each other.
Neurotransmittere som gammaaminosmørsyre er kemiske stoffer, som muliggør kommunikation mellem nervecellerne.
Neurotransmitters such as GABA are chemicals that allow nerve cells to communicate with each other.
Neutralisationstiter (50% effektiv koncentration [EC50]) udtrykkes som den antistof- koncentration, der er nødvendig for at reducere detektion af RSV-antigen med 50% sammenlignet med ubehandlede virus-inficerede celler.
The neutralization titre (50% effective concentration [EC50]) is expressed as the antibody concentration required to reduce detection of RSV antigen by 50% compared with untreated virus-infected cells.
Neutraliserende anti-erytropoietin antistof-medieret pure red cell aplasia (PRCA) er blevet rapporteret; hyppigheden er ikke kendt.
Neutralising anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA), has been reported, frequency unknown.
Neutraliserende antistoffer (inhibitorer)
Neutralising antibodies (inhibitors)
Neutraliserende antistoffer (inhibitorer): Medicinen holder op med at virke korrekt (blødning varer ved).
Inhibitors: the medicine stops working properly (continuous bleeding).
Neutraliserende antistoffer blev detekteret hos 19 ud af 299 patienter i studie 1.
Neutralizing antibodies were detected in 19 of 299 patients in Study 1.
neutraliserende faktorer, som udvikledes hos cancerpatienter, der blev behandlet systemisk, var 2,9 % og hos patienter med kronisk hepatitis 6,2 %.
The clinical incidence of neutralising factors developing in cancer patients treated systemically is 2.9 % and in chronic hepatitis patients is 6.2 %.
Neutraliserende JEV-antistoftitre blev målt i forhold til stammen SA14- 14-2.
Neutralising antibody titers against JEV were measured against the JEV strain SA14-14-2.
Neutralisering af VEGF’s biologiske aktivitet hæmmer vaskulariseringen af tumorer, normaliserer den tilbageblevne tumorvaskulatur, hæmmer dannelsen af ny tumorvaskulatur og hæmmer derved tumorvæksten.
Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.
neutrofil dermatosis, fotosensitivitet, pigmenteringsforstyrrelse, panniculitis, hudsår, bulløse tilstande, neglelidelser, palmoplantar erytrodysæstesisyndrom, hårlidelser
neutrophilic dermatosis, photosensitivity, pigmentation disorder, panniculitis, skin ulcer, bullous conditions, nail disorder, palmar-plantar erythrodysesthesia syndrome, hair disorder
Neutrofil elastase kan forårsage beskadigelse, hvis virkningen ikke kontrolleres (for eksempel i tilfælde af, at du har alfa-1- proteinasehæmmer-mangel).
Neutrophil elastase can cause damage if its action is not controlled (for example, in case you have an alpha1-proteinase inhibitor deficiency).
Neutrofile er en del af kroppens naturlige forsvar (immunsystemet) og er med til at bekæmpe infektioner.
Neutrophils are part of the immune system (the body’s natural defences) and help to fight infection.
Neutrofile granulocytter
Neutrophils
Neutrofile granulocytter ≥ 1.500/mm3
Absolute neutrophil counts ≥ 1,500/mm3
Neutrofile ≥ 1,5 x 109/l
Neutrophils ≥1.5 x 109/l
Neutrofiler  1.500/mm3
Neutrophil count  1,500/mm3
Neutrofiler, der er dannet som respons på filgrastim, udviser normal eller forøget funktion påvist ved test af kemotaktisk eller fagocytotisk funktion.
Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function.
Neutrofiler, monocytter, eosinofiler, basofiler og natural killer celler er kun midlertidigt påvirkede af LEMTRADA.
Neutrophils, monocytes, eosinophils, basophils, and natural killer cells are only transiently affected by LEMTRADA.
Neutrofiltal på under 1.500/mm3.
Neutrophil counts less than 1,500/mm3.
Neutrofiltal ≥1.500/mm3
Neutrophil Count ≥ 1,500/mm3
Neutropen feber/neutropen sepsis blev rapporteret hos 6 % af de asiatiske patienter mod 1 % af de hvide patienter.
Neutropenic fever/neutropenic sepsis was reported in 6% of Asian patients compared to 1% of White patients.
Neutropen infektion
Neutropenic infection
Neutropen infektion, luftvejsinfektion, infektion
Neutropenic infection, respiratory tract infection, infection
Neutropen infektion; infektion (G3/4: 11,7 %)
Neutropenic infection; Infection (G3/4: 11.7%)
Neutropen infektion; Infektion (G3/4: 11,7%)
Neutropenic infection; Infection (G3/4: 11.7%)
Neutropene (ANC, celler/mm3500)
69/114 (60.5%)
neutropeni
neutropenia,
Neutropeni
Thrombocythemia
Neutropeni (1),(2)
Neutropenia (1),(2)
Neutropeni (2)
Neutropenia (2)
Neutropeni (3,6 %)
Neutropenia (3.6%)
Neutropeni (53,6 %) (G3/4: 46,0 %)
Neutropenia (53.6%) (G3/4: 46.0%)
Neutropeni (absolut neutrofiltal [ANC] < 1,5 x 109/l) er hyppigt observeret ved anvendelse af et andet lægemiddel, der hæmmer IL-1, i en anden patientpopulation (reumatoid artritis) end CAPS.
Neutropenia (absolute neutrophil count [ANC] < 1.5 x 109/l) has been observed commonly with another medicinal product that inhibits IL-1 used in a patient population (rheumatoid arthritis) other than CAPS.
Neutropeni (absolut neutrofiltal [ANC] <1,5 x 109/L) og leukopeni er observeret ved lægemidler, der hæmmer IL-1, inklusive Ilaris.
Neutropenia (absolute neutrophil count [ANC] < 1.5 x 109/l) and leukopenia have been observed with medicinal products that inhibit IL-1, including Ilaris.
Neutropeni (ANC < 1.000 /mm3 )
Neutropenia (ANC < 1000/mm3 ) or
Neutropeni (ANC  1,5 x 109/l) blev rapporteret hos 2,4% af patienterne som fik Kineret sammenlignet med 0,4% af placebopatienterne.
Neutropenia (ANC < 1.5 x 109/l) was reported in 2.4% patients receiving Kineret compared with 0.4% of placebo patients.
Neutropeni (ANC 1,5 x 109/l) blev rapporteret hos 2,4% af patienterne som fik Kineret sammenlignet med 0,4% af placebopatienterne.
Neutropenia (ANC < 1.5 x 109/l) was reported in 2.4% patients receiving Kineret compared with 0.4% of placebo patients.
Neutropeni (febril neutropeni, neutropeni, nedsat neutrofiltal).
Neutropenia (Febrile neutropenia, Neutropenia, Neutrophil count decreased).
Neutropeni (G3/4:
Neutropenia (G3/4: 83.5%);
Neutropeni (G3/4:
Neutropenia G3/4: 83.5%)
Neutropeni (G3/4: 32 %);
Neutropenia (G3/4: 63%);
Neutropeni (G3/4: 32 %); Anæmi (G3/4: 4,9 %)
Anaemia (G3/4: 3%); Neutropenia (G3/4: 59.2%);
Neutropeni (G3/4: 32 %); Febril neutropeni (inclusive neutropeni associeret med feber og brug af antibiotika) eller neutropenisk sepsis
Neutropenia (G3/4: 32%); Febrile neutropenia (includes neutropenia associated with fever and antibiotic use) or neutropenic sepsis
Neutropeni (G3/4: 32 %); Febril neutropeni (inkluderer neutropeni forbundet med feber og brug af antibiotika) eller neutropenisk sepsis
Neutropenia (G3/4: 32%); Febrile neutropenia (includes neutropenia associated with fever and antibiotic use) or neutropenic sepsis
Neutropeni (G3/4: 32 %); Febril neutropeni (inklusiv neutropeni associeret med feber og brug af antibiotika) eller neutropenisk sepsis
Neutropenia (G3/4: 32%); Febrile neutropenia (includes neutropenia associated with fever and antibiotic use) or neutropenic sepsis
Neutropeni (G3/4: 32%);
Neutropenia (G3/4: 32%);
Neutropeni (G3/4: 59,2 %);
Neutropenia (G3/4: 59.2%);
Neutropeni (G3/4: 59,2 %);
Neutropenia (Grade 4)
Neutropeni (G3/4: 63 %);
Neutropenia (G3/4: 63%);
Neutropeni (G3/4: 63%);
Neutropenia (G3/4: 63%);
Neutropeni (G3/4: 76,3 %);
Neutropenia (G3/4: 76.3%);
Neutropeni (G3/4: 76,3 %);
Neutropenia G3/4: 76.3%)
Neutropeni (G3/4: 76,3 %);
Neutropenia G3/4: 83.5%)
Neutropeni (G3/4: 76,3%);
Neutropenia (G3/4: 76.3%);
Neutropeni (G3/4: 83,2%);
Neutropenia (G3/4: 83.2%); Thrombocytopenia (G3/4: 8.8%);
Neutropeni (G3/4: 83,5%);
Neutropenia (G3/4: 83.5%);
Neutropeni (G4:
Neutropenia (G4: 51.5%);
Neutropeni (G4:
Neutropenia (G4: 91.7%);
Neutropeni (G4: 51,5 %);
Neutropenia (G4: 51.5%);
Neutropeni (G4: 51,5 %);
Neutropenia (G4: 91.7%);
Neutropeni (G4: 74,6 %);
Neutropenia (G4: 76.4%)
Neutropeni (G4: 76,4 %);
Neutropenia (G4: 76.4%);
Neutropeni (G4: 76,4%);
Neutropenia (G4: 76.4%);
Neutropeni (G4: 91,7 %);
Neutropenia (G4: 54.2%);
Neutropeni (G4: 91,7 %);
Neutropenia (G4: 91.7%);
Neutropeni (G4: 91,7%);
Neutropenia (G4: 91.7%);
Neutropeni (grad 4)
Neutropenia (Grade 4)
Neutropeni (meget almindelig), febril neutropeni (almindelig) og septisk shock (ikke almindelig).
Neutropenia (very common), febrile neutropenia (common) and septic shock (uncommon).
Neutropeni (neutrofiltælling)
Neutropenia (neutrophil count)
Neutropeni < 500/mm3 varende i mere end 5 dage eller associeret med feber eller infektion
Neutropenia < 500/mm3 lasting for more than 5 days or associated with fever or infection
Neutropeni a,b
Neutropenia a,b
Neutropeni af grad 3 eller højere forekom hyppigere hos patienter i ONIVYDE + 5-FU/LV-gruppen (27,4 %) end i 5-FU/LV-gruppen (1,5 %).
Grade 3 or higher neutropenia occurred more frequently in patients treated with ONIVYDE+5-FU/LV (27.4%) compared to patients treated with 5-FU/LV (1.5%).
Neutropeni Agranulocytose
Neutropenia Agranulocytosis
Neutropeni eller lymfopeni (grad 3 - 4), trombocytopeni (grad 3 - 4)
Neutropenia or lymphopenia (Grade 3 – 4), thrombocytopenia (Grade 3 – 4)
Neutropeni eller lymfopeni (grad 3-4),
Neutropenia or lymphopenia (grade 3-4), thrombocytopenia (grade 3-4)
Neutropeni er almindeligt rapporteret, når olanzapin og valproat anvendes samtidig (se afsnit 4.8).
Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly (see section 4.8).
Neutropeni forekom hos 45,3 % af patienterne, som fik pomalidomid plus lavdosis dexamethason (Pom + LD-Dex), og hos 19,5 % af patienterne, som fik højdosis dexamethason (HD-Dex).
Neutropenia occurred in 45.3% of patients who received pomalidomide plus low dose dexamethasone (Pom + LD-Dex), and in 19.5% of patients who received high dose dexamethasone (HD-Dex).
Neutropeni forsvandt efter 35 dage hos alle patienter, der blev fulgt op.
Neutropenia resolved in 35 days in all patients who were followed.
Neutropeni grad 4 (ANC 500/mm3) > 7 dage
Neutropenia Grade 4 (ANC  500/mm3) > 7 days
Neutropeni i grad 3-4 forekom hos 36,7 % af patienterne i ZALTRAP-armen og hos 29,5 % i placeboarmen.
Grade 3-4 neutropenia was observed in 36.7% of patients treated with the ZALTRAP/FOLFIRI regimen compared to 29.5% patients treated with the placebo/FOLFIRI regimen.
Neutropeni kan forekomme i forbindelse med opportunistiske infektioner, der infiltrerer knoglemarven, såsom Mycobacterium avium-kompleks eller ved maligne sygdomme som lymfom.
Neutropenia may be due to bone marrow infiltrating opportunistic infections such as Mycobacterium avium complex or malignancies such as lymphoma.
Neutropeni kan være forårsaget af opportunistiske infektioner i knoglemarven, såsom Mycobakterie avium-kompleks, eller maligniteter, såsom lymfomer.
Neutropenia may be due to bone marrow-infiltrating opportunistic infections such as Mycobacterium avium complex or malignancies such as lymphoma.
Neutropeni Leukopeni Anæmi Trombocytopeni
Neutropenia Leukopenia Anaemia Thrombocytopenia
Neutropeni og agranulocytose forsvandt, når behandlingen blev seponeret.
Neutropenia and agranulocytosis resolved once therapy was withdrawn.
neutropeni og uveitis er påkrævet
reactions including neutropenia
neutropeni og uveitis, er påkrævet
neutropenia and uveitis is warranted
Neutropeni Trombocytopeni
Neutropenia Thrombocytopenia
Neutropeni Trombocytopeni Anæmi Leukopeni
Neutropoenia Thrombocytopoenia Anaemia Leukopoenia
Neutropeni Trombocytopeni Febril neutropeni Anæmi Pancytopeni
Neutropenia Thrombocytopenia Febrile neutropenia Anaemia Pancytopenia
Neutropeni var den hyppigst rapporterede grad 3 eller 4 hæmatologiske bivirkning hos patienter med relaps / refraktær myelomatose, efterfulgt af anæmi og trombocytopeni.
Neutropenia was the most frequently reported Grade 3 or 4 haematological adverse reaction in patients with relapsed/refractory multiple myeloma, followed by anaemia and thrombocytopenia.
Neutropeni var grad 3 eller 4 hos 41,7 % af patienterne, som fik Pom + LD-Dex, sammenlignet med 14,8 % i HD-Dex-armen.
Neutropenia was Grade 3 or 4 in 41.7% of patients who received Pom + LD-Dex, compared with 14.8% who received HD-Dex.
Neutropeni var ikke forbundet med en øget frekvens af alvorlige infektioner blandt MabThera-behandlede patienter.
Neutropenia was not associated with an observed increase in serious infection in MabThera-treated patients.
Neutropeni var tilstede i >7 dage hos 41 % og i
Neutropenia was present for > 7 days in 41 % and for
Neutropeni ved baseline
Neutropenia at baseline
Neutropeni Vedvarende svær neutropeni svinder normalt spontant, når Diacomit seponeres.
Neutropenia Persistent severe neutropenia usually resolves spontaneously when Diacomit is stopped.
neutropeni – lavt indhold af neutrofile granulocytter, en type hvide blodlegemer (fremgår af dine blodprøver) – dette kan gøre dig mere modtagelig for infektioner
low levels of “neutrophils” a type of white blood cell (neutropenia) –this can make you more likely to get infections and be shown up in blood tests
Neutropeni ≥ grad 3 med feber, neutropeni grad 4 i mere end 7 dage, thrombocyttal < 10.000 celler/μl
≥ Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, a platelet count < 10,000 cells/μL
neutropeni  lavt indhold af neutrofile granulocytter, en type hvide blodlegemer (fremgår af dine blodprøver) – dette kan gøre dig mere modtagelig for infektioner
low levels of “neutrophils” a type of white blood cell (neutropenia) – this can make you more likely to get infections and be shown up in blood tests
neutropeni*
neutropaenia
Neutropeni*
Neutropenia
Neutropeni* (grad 3 = 26 %, grad 4 = 24 %),
Neutropenia* (Grade 3 = 26%, Grade 4 = 24%),
Neutropeni,
Musculoskeletal
Neutropeni,
Neutropenia,
Neutropeni, (se pkt 4.4)
(see section 4.4)
neutropeni, anæmi, leukopeni
neutropaenia, anaemia, leukopaenia
Neutropeni, anæmi, leukopeni, lymfopeni, trombocytopeni
Neutropenia, anaemia, leucopenia, lymphopenia, thrombocytopenia
Neutropeni, inklusive svær neutropeni
including severe
neutropeni, leukopeni,
neutropenia, leucopenia,
Neutropeni, leukopeni, anæ mi, lymfadenopati.
Neutropenia, leucopenia, anaemia, lymphadenopathy.
Neutropeni, leukopeni, anæmi, , trombocytope ni
Neutropenia, leukopenia, anaemia, thrombo- cytopenia
Neutropeni, leukopeni, anæmi, trombocyto peni
Neutropenia, leukopenia, anaemia, thrombo- cytopenia
neutropeni, leukopeni, trombocytopeni, lymfopeni, eosinofili
neutropenia, leukopenia, thrombocytopenia, lymphopenia, eosinophilia
Neutropeni, pancytopeni, leukopeni
Neutropenia, Pancytopenia, Leukopenia
Neutropeni, trombocytopeni
Febrile neutropaenia, lymphopaenia
Neutropeni, trombocytopeni og anæmi var de hyppigste rapporterede hæmatologiske tilfælde, der blev rapporteret ved både kombinationsbehandling med Caelyx og bortezomib og bortezomib monoterapi.
Neutropaenia, thrombocytopaenia, and anaemia were the most frequently reported hematologic events reported with both combination therapy of Caelyx plus bortezomib and bortezomib monotherapy.
Neutropeni,leukopeni,lymfopeni,anæmi, trombocytopeni
Neutropenia, leukopenia, lymphopenia, anaemia, thrombocytopenia
Neutropeni/leukopeni (lavt antal hvide blodlegemer)
Neutropenia/leukopenia (low number of white blood cells)
neutropeni1, nedsat leukocyttal2, nedsat hæmoglobin2, nedsat trombocyttal2
neutropenia1, decreased white blood cell count2, decreased haemoglobin2, decreased platelet count2
Neutropeni2, anæmi2, trombocytopeni1
Neutropenia2, anaemia2, thrombocytopenia1
Neutropeni: Alvorlig (neutrofiltal < 0,5 x 109/l) under behandlingsperiode 1 blev observeret hos 55 % af patienterne og med en varighed ≥ syv dage hos 20 % og totalt set hos 77 % af patienterne (39 % af behandlingerne).
Neutropenia: Severe (neutrophil count < 0.5 x 109/l) during course 1 was seen in 55 % of the patients and with duration ≥ seven days in 20 % and overall in 77 % of patients (39 % of courses).
Neutropeni: Alvorlig neutropeni (grad 4 - neutrofiltal < 0,5 x 109/l) sås hos 32 % af patienterne i 13 % af behandlingsperioderne.
Neutropenia: Severe neutropenia (Grade 4 - neutrophil count < 0.5 x 109/l) occurred in 32 % of patients in 13 % of courses.
Neutropeni: Alvorlig neutropeni (neutrofiltal < 0,5 x 109/l) under behandlingsperiode 1 blev observeret hos 55 % af patienterne og med en varighed ≥ syv dage hos 20 % og totalt set hos 77 % af patienterne (39 % af behandlingerne).
Neutropenia: Severe (neutrophil count < 0.5 x 109/l) during course 1 was seen in 55 % of the patients and with duration ≥ seven days in 20 % and overall in 77 % of patients (39 % of courses).
Neutropeni: Alvorlig neutropeni (neutrofiltal < 0,5 x 109/l) under behandlingsperiode 1 blev observeret hos 55 % af patienterne og med en varighed  syv dage hos 20 % og totalt set hos 77 % af patienterne (39 % af behandlingerne).
Neutropenia: Severe (neutrophil count < 0.5 x 109/l) during course 1 was seen in 55 % of the patients and with duration  seven days in 20 % and overall in 77 % of patients (39 % of courses).
Neutropeni: Alvorlig neutropeni(neutrofiltal < 0,5 x 109/l) under behandlingsperiode 1 blev observeret hos 55 % af patienterne og med en varighed ≥ syv dage hos 20 % og totalt set hos 77 % af patienterne (39 % af behandlingerne).
Neutropenia: Severe (neutrophil count < 0.5 x 109/l) during course 1 was seen in 55 % of the patients and with duration ≥ seven days in 20 % and overall in 77 % of patients (39 % of courses).
Neutropeni; thrombocytopeni^; pancytopeni; leukopeni^; anæmi^
Neutropenia; Thrombocytopenia^; Pancytopenia; Leukopenia^; Anaemia^
Neutropeni<1,0-0,5x109/l (CTCAE klasse 3) blev rapporteret i 18 ud af 3.430 (0,5 %) patienter på secukinumab, med ingen dosisafhængighed og ingen tidsmæssig tilknytning til infektioner i 15 ud af 18 tilfælde.
Neutropenia <1.0-0.5x109/l (CTCAE Grade 3) was reported in 18 out of 3,430 (0.5%) patients on secukinumab, with no dose dependence and no temporal relationship to infections in 15 out of 18 cases.
Neutropeni^, trombocytopeni^, anæmi, blødningsforstyrrelser^, leukopeni
Thrombocytopenia^, Anaemia, Leucopenias
Neutropeni^, trombocytopeni^, anæmi, leukopeni
Metabolism and Nutrition Disorders
Neutropeni^, trombocytopeni^, anæmi, leukopeni
Thrombocytopenia^, Anaemia, Leucopenias
Neutropenia (22%)
Neutropeniaa (22%)
Neutropenia*
Neutropeniaa
Neutropenib
Neutropeniab
Neutropenisk infektion
Post-marketing experience
Neutropenisk infektion (G3/4: 2,6 %)
(G3/4: 2.6%)
Neutropenisk infektion (G3/4: 2,6 %).
Neutropenic infection (G3/4: 2.6%)
Neutropenisk infektion (G3/4: 2,7%)
With primary
Neutropenisk infektion (grad 3- 4)
Neutropenic infection (Grade 3-4)
Neutropenisk infektion (grad 3-4)
Neutropenic infection (Grade 3-4)
Neutropenisk infektion/sepsis (1) Urinvejsinfektion
Neutropenic infection/sepsis (1) Urinary tract infection Nasopharyngitis
Neutropenisk infektion; Infektion (G3/4: 11,7 %)
Infection (G3/4: 6.3%); Neutropenic infection
Neutropeniske komplikationer hos patienter, der får TAC med eller uden G-CSF-profylakse (GEICAM 9805)
G-CSF was used for secondary prophylaxis in 19.3% of patients (10.7% of the cycles).
Neutropeniske komplikationer hos patienter, der får TAC med eller uden G-CSF-profylakse(GEICAM 9805)
Neutropenic complications in patients receiving TAC with or without primary G-CSF prophylaxis (GEICAM 9805)
Neutrófilos < 2.000/mm3
Platelets < 80,000/mm3
Nevanac 1 mg/ml er indiceret til voksne til:
NEVANAC 1 mg/ml is indicated in adults for:
Nevanac 1 mg/ml øjendråber nepafenac.
NEVANAC 1 mg/ml eye drops Nepafenac
Nevanac 1 mg/ml øjendråber, suspension
NEVANAC 1 mg/ml eye drops, suspension
Nevanac 1 mg/ml øjendråber, suspension nepafenac
NEVANAC 1 mg/ml eye drops, suspension Nepafenac
nevanac 3 mg/ml
Nevanac 3mg/ml
Nevanac 3 mg/ml øjendråber nepafenac.
NEVANAC 3 mg/ml eye drops Nepafenac
Nevanac 3 mg/ml øjendråber, suspension
NEVANAC 3 mg/ml eye drops, suspension
Nevanac 3 mg/ml øjendråber, suspension er indiceret til voksne til:
NEVANAC 3 mg/ml eye drops, suspension is indicated in adults for:
Nevanac 3 mg/ml øjendråber, suspension nepafenac
NEVANAC 3 mg/ml eye drops, suspension Nepafenac
Nevanac anbefales ikke til disse patienter, før der foreligger yderligere data.
Its use is not recommended in these patients until further data become available.
Nevanac anbefales ikke under graviditet.
The use of NEVANAC is not recommended during pregnancy.
Nevanac bør anvendes med forsigtighed hos patienter med kendt blødningstendens eller som får andre lægemidler, der kan forlænge blødningstiden.
NEVANAC should be used with caution in patients with known bleeding tendencies or who are receiving other medicinal products which may prolong bleeding time.
Nevanac bør ikke anvendes til kvinder i den fertile alder, som ikke anvender sikker kontraception.
NEVANAC should not be used by women of child bearing potential not using contraception.
Nevanac er beregnet til voksne:
NEVANAC is to be used by adults:
Nevanac er en væske (lys gul til lys orange suspension), der fås i en 5 ml plasticflaske med skruelåg.
NEVANAC is a liquid (light yellow to light orange suspension) supplied in a pack containing one 5 ml plastic bottle with a screw cap.
Nevanac er ikke undersøgt hos patienter med leversygdom eller nedsat nyrefunktion.
NEVANAC has not been studied in patients with hepatic disease or renal impairment.
Nevanac indeholder benzalkoniumchlorid
NEVANAC contains benzalkonium chloride
Nevanac indeholder benzalkoniumchlorid, der kan medføre øjenirritation og misfarvning af bløde kontaktlinser.
NEVANAC contains benzalkonium chloride which may cause eye irritation and is known to discolour soft contact lenses.
Nevanac indeholder benzalkoniumchlorid, der kan medføre øjenirritation og misfarvning af bløde kontaktlinser.
NEVANAC contains benzalkonium chloride which may cause irritation and is known to discolour soft contact lenses.
Nevanac indeholder det aktive stof, nepafenac, og tilhører en gruppe af lægemidler, der kaldes non- steroide antiinflammatoriske stoffer (NSAID-præparater).
NEVANAC contains the active substance nepafenac, and belongs to a group of medicines called non- steroidal anti-inflammatory drugs (NSAIDs).
Nevanac indeholder det aktive substans, nepafenac, og tilhører en gruppe af lægemidler, der kaldes non-steroide antiinflammatoriske stoffer (NSAID-præparater).
NEVANAC contains the active substance nepafenac, and belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAIDs).
Nevanac indeholder et konserveringsmiddel (benzalkoniumchlorid), som kan give irritation i øjnene, misfarve bløde kontaktlinser og give bivirkninger i hornhinden (øjeæblets overflade).
The preservative in NEVANAC, benzalkonium chloride can discolour soft lenses and may cause eye irritation and corneal side effects (eye surface problems).
Nevanac indeholder et konserveringsmiddel (benzalkoniumchlorid), som kan give irritation i øjnene, misfarve bløde kontaktlinser og give bivirkninger i hornhinden (øjeæblets overflade).
The preservative in NEVANAC, bezalkonium chloride, can discolour soft lenses and may cause eye irritation and corneal side effects (eye surface problems).
Nevanac kan anvendes under amning.
NEVANAC can be used during breast-feeding.